Swiss pharma giants fined by France in ongoing eye drug clash
The two drugs are used to to treat patients with blindness-causing macular degeneration.
Keystone/Jay
The pharmaceutical companies Novartis and Roche have been fined €444 million (CHF481 million) by the French competition authority for applying abusive practices to push costly eye injection Lucentis over a cheaper drug.
This content was published on
2 minutes
swissinfo.ch with Reuters/ug
Português
pt
França processa farmacêuticas suíças por injeção de colírio
The two Swiss pharma companies abused their dominant position to push Lucentis at the expense of the drug Avastin, the French competition watchdog announced on Wednesday.
It added that Novartis was also punished for “unjustifiably exaggerating” Avastin’s risks.
Novartis, which said it would appeal, is facing high stakes in protecting Lucentis sales in Europe, after the uptake of its newest eye drug, Beovu, has been slowed by safety concerns.
Novartis must pay €385 million and Roche about €60 million, according to the decision.
Roche and Novartis are partners on Lucentis, with Roche selling it in the United States and Novartis selling it in Europe.
Running battle
The fines are the latest development in a running battle between the drug makers and countries where some doctors have turned to Roche’s cheaper Avastin to replace costly Lucentis, to treat patients with blindness-causing macular degeneration (AMD).
Lucentis was developed for AMD but works like cancer drug Avastin by inhibiting blood vessel growth. Avastin is used “off-labelExternal link” to treat AMD.
The French authority said Lucentis, injected roughly once per month, costs €1,161 per injection, while Avastin runs at €30 to €40 per shot.
Similar disputes have emerged elsewhere. In 2018, Novartis and Roche lost a bid in Britain to block doctors from making Avastin the preferred option for AMD.
RocheExternal link said it was disappointed and would “assess” the situation.
NovartisExternal link said a French rule allowing off-label use of medicines in diseases with approved treatments threatens the system of ensuring safe and effective drugs.
“This decision relies on a gross misinterpretation of the facts and a distortion of previous case law,” Novartis said.
Polish climber dies near Zermatt after falling into crevasse
This content was published on
A Polish mountaineer died on Sunday after falling into a crevasse on the Monte Rosa glacier in the Swiss resort of Zermatt.
This content was published on
Production in Switzerland's secondary sector fell in the second quarter of 2025. The decline was more pronounced in the construction sector than for industry.
Swiss army recruits remain in hospital after gruelling test exercise
This content was published on
Four potential recruits for the elite Swiss grenadier unit were hospitalised last week after taking part in a gruelling exercise in hot weather. Three remain in hospital with one placed temporarily in an artificial coma.
University of Basel to mark 125th anniversary of Nietzsche’s death
This content was published on
This month the University of Basel is celebrating the German philosopher Friedrich Nietzsche, who was a professor there from 1869 to 1879. August 25th marks the 125th anniversary of his death.
Trump tariffs: Swiss brands struggle to adapt to 39% tariff
This content was published on
Swiss brands like Victorinox, the manufacturer of the iconic pocket knife, are struggling to adapt to the 39% tariff imposed by the United States on imports of Swiss goods.
Fish and aquatic plants are under ‘severe pressure’ in Swiss rivers and lakes
This content was published on
Fish, aquatic plants and other animals in Swiss rivers, lakes and streams remain under 'severe pressure', according to the Federal Office for the Environment.
Swatch withdraws ‘slanted eyes’ ad after China uproar
This content was published on
The Swiss watch manufacturer Swatch has apologised and withdrawn an advertising campaign worldwide following accusations of racism in China. The ad features a model pulling the corners of his eyes.
Police identify bodies of three climbers who died in Swiss Alps
This content was published on
Police have formally identified the bodies of three climbers who died in the Upper Valais region in early August: they are from Germany, France and Austria.
Bern exhibition reunites Kirchner paintings after 92 years
This content was published on
The painting Sonntag der Bergbauern (Alpsonntag) [Sunday of the Mountain Farmers (Alp Sunday) by Ernst Ludwig Kirchner (1880-1938) is being transferred from Berlin to Bern to feature in an upcoming exhibition at Kunstmuseum Bern.
Voters approve extension of Engadine Airport in Switzerland
This content was published on
Residents in the Upper Engadine region gave the greenlight on Sunday to the expansion of the regional airport at Samedan, one of Europe’s highest airports (1,707 metres) that serves the nearby resorts of St Moritz and Davos.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche clears drug that caused vision loss in India
This content was published on
“In India, Roche has completed an assessment of the available information on the batch reported to have been used at C.H Nagri Eye Hospital in Ahmedabad, Gujarat. We can confirm that based on the information available, there is no reason to believe there were quality problems with the Avastin (Bevacizumab) vials in this batch,” a…
Novartis pays big fine for bribing doctors in the US
This content was published on
Swiss pharma company Novartis will pay $729 million to US authorities in an out-of-court settlement over charges that the company bribed doctors to use its drugs.
Can big pharma’s money solve the antibiotics crisis?
This content was published on
Big pharmaceutical companies are investing nearly $1 billion in a fund to bring new antibiotics to patients. What's the catch?
Are Big Pharma’s big innovation plans what we need?
This content was published on
Our analysis of what the biggest global companies in Switzerland are up to. This week: Big Pharma's R&D plans, coronavirus impact, and #cryptoleaks.
Big companies get ready for a contentious political season
This content was published on
Our analysis of what the biggest global companies in Switzerland are up to. This week: companies mixed up in politics and foreign aid.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.